Literature DB >> 33539400

Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda.

Rachel K Lim1, Fred C Semitala2,3,4, Elly Atuhumuza3, Laban Sabiti4, Jane Namakula-Katende4, Winnie R Muyindike5, Moses R Kamya2,3, David Dowdy6, Adithya Cattamanchi7.   

Abstract

A 12-dose weekly regimen of rifapentine plus isoniazid (3HP) is recommended for the prevention of active tuberculosis (TB); however, it is unclear whether 3HP should be provided by directly observed therapy (DOT) or self-administered therapy (SAT). In addition, the introduction of patient informed choice between delivery modalities may have a positive impact on factors leading to treatment completion. The authors randomized 252 participants with HIV to a hypothetical scenario of providing preventive therapy by either DOT or an informed choice between DOT and SAT. Out of 104 participants who were randomized to a choice between DOT and SAT, 103 chose therapy by SAT. Participants rated their level of confidence and intention to complete therapy. Compared to those assigned to the DOT scenario, patients assigned to the choice scenario expressed greater confidence and intention to complete preventive therapy. Convenience and travel required to complete 3HP therapy were important factors in deciding between delivery modalities. Those assigned to DOT identified more barriers to completing therapy than those given a choice. Empowering patients to make informed decisions about how they receive TB preventive therapy may improve completion rates.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33539400      PMCID: PMC7861427          DOI: 10.1371/journal.pone.0246113

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  13 in total

1.  Using self-efficacy judgments to predict characteristics of lapses to smoking.

Authors:  Chad J Gwaltney; Saul Shiffman; Jean A Paty; Ken S Liu; Jon D Kassel; Maryann Gnys; Mary Hickcox
Journal:  J Consult Clin Psychol       Date:  2002-10

Review 2.  Decision aids for people facing health treatment or screening decisions.

Authors:  Dawn Stacey; France Légaré; Krystina Lewis; Michael J Barry; Carol L Bennett; Karen B Eden; Margaret Holmes-Rovner; Hilary Llewellyn-Thomas; Anne Lyddiatt; Richard Thomson; Lyndal Trevena
Journal:  Cochrane Database Syst Rev       Date:  2017-04-12

3.  The global prevalence of latent tuberculosis: a systematic review and meta-analysis.

Authors:  Adam Cohen; Victor Dahl Mathiasen; Thomas Schön; Christian Wejse
Journal:  Eur Respir J       Date:  2019-09-12       Impact factor: 16.671

4.  Patient preference for latent tuberculosis infection preventive treatment: a discrete choice experiment.

Authors:  Na Guo; Carlo A Marra; J Mark FitzGerald; R Kevin Elwood; Aslam H Anis; Fawziah Marra
Journal:  Value Health       Date:  2011-07-29       Impact factor: 5.725

Review 5.  The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis.

Authors:  Hannah Alsdurf; Philip C Hill; Alberto Matteelli; Haileyesus Getahun; Dick Menzies
Journal:  Lancet Infect Dis       Date:  2016-08-10       Impact factor: 25.071

6.  Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.

Authors:  Robert Belknap; David Holland; Pei-Jean Feng; Joan-Pau Millet; Joan A Caylà; Neil A Martinson; Alicia Wright; Michael P Chen; Ruth N Moro; Nigel A Scott; Bert Arevalo; José M Miró; Margarita E Villarino; Marc Weiner; Andrey S Borisov
Journal:  Ann Intern Med       Date:  2017-11-07       Impact factor: 25.391

7.  Patient choice promotes adherence in preventive treatment for latent tuberculosis.

Authors:  T W Rennie; G H Bothamley; D Engova; I P Bates
Journal:  Eur Respir J       Date:  2007-07-11       Impact factor: 16.671

8.  Factors associated with antiretroviral adherence among HIV-infected women with children.

Authors:  Debra A Murphy; Lisa Greenwell; Dannie Hoffman
Journal:  Women Health       Date:  2002

Review 9.  Patient adherence to tuberculosis treatment: a systematic review of qualitative research.

Authors:  Salla A Munro; Simon A Lewin; Helen J Smith; Mark E Engel; Atle Fretheim; Jimmy Volmink
Journal:  PLoS Med       Date:  2007-07-24       Impact factor: 11.069

10.  Barriers in the access, diagnosis and treatment completion for tuberculosis patients in central and western Nepal: A qualitative study among patients, community members and health care workers.

Authors:  Sujan Babu Marahatta; Rajesh Kumar Yadav; Deena Giri; Sarina Lama; Komal Raj Rijal; Shiva Raj Mishra; Ashish Shrestha; Pramod Raj Bhattrai; Roshan Kumar Mahato; Bipin Adhikari
Journal:  PLoS One       Date:  2020-01-15       Impact factor: 3.240

View more
  4 in total

1.  Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.

Authors:  Fred C Semitala; Jillian L Kadota; Allan Musinguzi; Juliet Nabunje; Fred Welishe; Anne Nakitende; Lydia Akello; Opira Bishop; Devika Patel; Amanda Sammann; Payam Nahid; Robert Belknap; Moses R Kamya; Margaret A Handley; Patrick P J Phillips; Anne Katahoire; Christopher A Berger; Noah Kiwanuka; Achilles Katamba; David W Dowdy; Adithya Cattamanchi
Journal:  PLoS Med       Date:  2021-12-16       Impact factor: 11.613

2.  Person-centred care and short oral treatment for rifampicin-resistant tuberculosis improve retention in care in Kandahar, Afghanistan.

Authors:  Anita Mesic; Sadiqullah Ishaq; Waliullah H Khan; Atiqullah Mureed; Htay Thet Mar; Ei Ei Khaing; Elkin Bermudez-Aza; Letitia Rose; Lutgarde Lynen; Mohammad Khaled Seddiq; Hashim Khan Amirzada; Kees Keus; Tom Decroo
Journal:  Trop Med Int Health       Date:  2022-01-17       Impact factor: 3.918

3.  HIV, tuberculosis, diabetes mellitus and hypertension admissions and premature mortality among adults in Uganda from 2011 to 2019: is the tide turning?

Authors:  Andrew Kazibwe; Kuteesa Ronald Bisaso; Andrew Peter Kyazze; Sandra Ninsiima; Phillip Ssekamatte; Felix Bongomin; Joseph Baruch Baluku; Davis Kibirige; George Patrick Akabwai; Moses R Kamya; Harriet Mayanja-Kizza; Pauline Byakika-Kibwika; Magid Kagimu; Robert Kalyesubula; Irene Andia-Biraro
Journal:  Trop Med Health       Date:  2022-08-10

4.  Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives.

Authors:  Fred C Semitala; Allan Musinguzi; Jackie Ssemata; Fred Welishe; Juliet Nabunje; Jillian L Kadota; Christopher A Berger; Achilles Katamba; Noah Kiwanuka; Moses R Kamya; David Dowdy; Adithya Cattamanchi; Anne R Katahoire
Journal:  Implement Sci Commun       Date:  2021-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.